DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
DEXISOMETHEPTENE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DEXISOMETHEPTENE
×
Maximum Phase:
2
First Approval:
None
UNII:
GOO8ZCK7RT
Molecule Type:
Small molecule
Molecular Formula:
C9H19N
Molecular Weight:
141.26
AlogP:
2.34
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
4.0
Source:
PULRODEMSTAT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PULRODEMSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C24H23F2N5O2
Molecular Weight:
451.48
AlogP:
3.2
PSA:
97.17
HBD:
1.0
HBA:
#RotB:
4.0
Source:
BMS-707035
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
BMS-707035
×
Maximum Phase:
2
First Approval:
None
UNII:
7PR4P7YOKT
Molecule Type:
Small molecule
Molecular Formula:
C17H19FN4O5S
Molecular Weight:
410.43
AlogP:
0.49
PSA:
121.6
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ODALASVIR
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Renal Insufficiency; Hepatitis C, Chronic
Nonstructural protein 5A inhibitor
ODALASVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
OVR52K7BDW
Molecule Type:
Small molecule
Molecular Formula:
C60H72N8O6
Molecular Weight:
1001.29
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MINOPAFANT
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Platelet activating factor receptor antagonist
MINOPAFANT
×
Maximum Phase:
2
First Approval:
None
UNII:
I7J5MAD9ZU
Molecule Type:
Small molecule
Molecular Formula:
C46H73N4O9+
Molecular Weight:
826.11
AlogP:
9.39
PSA:
136.82
HBD:
1.0
HBA:
#RotB:
28.0
Source:
DEXTROMETHADONE
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Restless Legs Syndrome; Depressive Disorder, Major
Unknown
DEXTROMETHADONE
×
Maximum Phase:
2
First Approval:
None
UNII:
S95RZH8AMH
Molecule Type:
Small molecule
Molecular Formula:
C21H27NO
Molecular Weight:
309.45
AlogP:
4.29
PSA:
20.31
HBD:
0.0
HBA:
#RotB:
7.0
Source:
PENTYLENETETRAZOL
2
Small molecule
Investigational
Unknown
Unknown
Idiopathic Hypersomnia; Respiratory Tract Diseases
Unknown
PENTYLENETETRAZOL
×
Maximum Phase:
2
First Approval:
None
UNII:
WM5Z385K7T
Molecule Type:
Small molecule
Molecular Formula:
C6H10N4
Molecular Weight:
138.17
AlogP:
0.4
PSA:
43.6
HBD:
0.0
HBA:
#RotB:
0.0
Source:
LB80380
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Hepatitis B, Chronic
DNA disrupting agent
LB80380
×
Maximum Phase:
2
First Approval:
None
UNII:
S9I9P4J8IU
Molecule Type:
Small molecule
Molecular Formula:
C22H34N5O8P
Molecular Weight:
527.52
AlogP:
3.24
PSA:
166.98
HBD:
1.0
HBA:
#RotB:
11.0
Source:
SEPRANOLONE
2
Small molecule
Investigational
Unknown
Unknown
Migraine Disorders
Unknown
SEPRANOLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
3P8Z6V53MU
Molecule Type:
Small molecule
Molecular Formula:
C21H34O2
Molecular Weight:
318.5
AlogP:
4.6
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
1.0
Source:
VABICASERIN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 2a (5-HT2a) receptor antagonist
VABICASERIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
2759C7222C
Molecule Type:
Small molecule
Molecular Formula:
C15H21ClN2
Molecular Weight:
264.8
AlogP:
2.49
PSA:
15.27
HBD:
1.0
HBA:
#RotB:
0.0
Source:
BLARCAMESINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Parkinson Disease; Rett Syndrome
Unknown
BLARCAMESINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1M49V1PBPL
Molecule Type:
Small molecule
Molecular Formula:
C19H24ClNO
Molecular Weight:
317.86
AlogP:
3.53
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
4.0
Source:
CONTEZOLID
2
Small molecule
Investigational
Unknown
Unknown
Bacterial Infections
Bacterial 70S ribosome inhibitor
CONTEZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
B669M62ELP
Molecule Type:
Small molecule
Molecular Formula:
C18H15F3N4O4
Molecular Weight:
408.34
AlogP:
2.82
PSA:
87.91
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TRO-40303
2
Small molecule
Investigational
Unknown
Unknown
Myocardial Infarction
Unknown
TRO-40303
×
Maximum Phase:
2
First Approval:
None
UNII:
3W389841RN
Molecule Type:
Small molecule
Molecular Formula:
C26H47NO2
Molecular Weight:
405.67
AlogP:
6.91
PSA:
52.82
HBD:
2.0
HBA:
#RotB:
8.0
Source:
SARCNU
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Central Nervous System Neoplasms; Colorectal Neoplasms
Unknown
SARCNU
×
Maximum Phase:
2
First Approval:
None
UNII:
BHB013S3MO
Molecule Type:
Small molecule
Molecular Formula:
C6H11ClN4O3
Molecular Weight:
222.63
AlogP:
-0.25
PSA:
96.07
HBD:
1.0
HBA:
#RotB:
5.0
Source:
MIPSAGARGIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Glioblastoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Sarcoplasmic/endoplasmic reticulum calcium ATPase inhibitor
MIPSAGARGIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Q032I35QMX
Molecule Type:
Small molecule
Molecular Formula:
C66H100N6O27
Molecular Weight:
1409.54
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GLPG-0259
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
MAP kinase-activated protein kinase 5 inhibitor
GLPG-0259
×
Maximum Phase:
2
First Approval:
None
UNII:
52EG7RFE6Y
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DANUGLIPRON
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Diabetes Mellitus, Type 2; Obesity
Glucagon-like peptide 1 receptor agonist
DANUGLIPRON
×
Maximum Phase:
2
First Approval:
None
UNII:
DN9IUI24GP
Molecule Type:
Small molecule
Molecular Formula:
C31H30FN5O4
Molecular Weight:
555.61
AlogP:
4.89
PSA:
113.5
HBD:
1.0
HBA:
#RotB:
9.0
Source:
ARAMCHOL
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Fatty Liver; Gallstones; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease
Unknown
ARAMCHOL
×
Maximum Phase:
2
First Approval:
None
UNII:
QE1Q24M65Y
Molecule Type:
Small molecule
Molecular Formula:
C44H79NO5
Molecular Weight:
702.12
AlogP:
10.61
PSA:
106.86
HBD:
4.0
HBA:
#RotB:
23.0
Source:
QUINAGOLIDE
2
Small molecule
Investigational
Unknown
Unknown
Ovarian Hyperstimulation Syndrome
Dopamine D2 receptor agonist
QUINAGOLIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
80Q9QWN15M
Molecule Type:
Small molecule
Molecular Formula:
C20H33N3O3S
Molecular Weight:
395.57
AlogP:
2.14
PSA:
72.88
HBD:
2.0
HBA:
#RotB:
7.0
Source:
NEZULCITINIB
2
Small molecule
Investigational
Unknown
Unknown
Acute Lung Injury; Severe Acute Respiratory Syndrome
Unknown
NEZULCITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C30H37N7O2
Molecular Weight:
527.67
AlogP:
3.8
PSA:
104.38
HBD:
3.0
HBA:
#RotB:
6.0
Source:
PLITIDEPSIN
2
Small molecule
Investigational
Unknown
Unknown
Liposarcoma; Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Neoplasms; Severe Acute Respiratory Syndrome
Elongation factor 1-alpha 2 inhibitor
PLITIDEPSIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Y76ID234HW
Molecule Type:
Small molecule
Molecular Formula:
C57H87N7O15
Molecular Weight:
1110.36
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
BGT-226
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Hamartoma Syndrome, Multiple; Neoplasms
PI3-kinase class I inhibitor
BGT-226
×
Maximum Phase:
2
First Approval:
None
UNII:
ZXE7F2GMJJ
Molecule Type:
Small molecule
Molecular Formula:
C28H25F3N6O2
Molecular Weight:
534.54
AlogP:
4.38
PSA:
77.21
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GLYCERYL TRIOLEATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GLYCERYL TRIOLEATE
×
Maximum Phase:
2
First Approval:
None
UNII:
O05EC62663
Molecule Type:
Small molecule
Molecular Formula:
C57H104O6
Molecular Weight:
885.45
AlogP:
18.1
PSA:
78.9
HBD:
0.0
HBA:
#RotB:
50.0
Source:
SQUARIC ACID DIBUTYL ESTER
2
Small molecule
Investigational
Unknown
Unknown
Herpes Labialis
Unknown
SQUARIC ACID DIBUTYL ESTER
×
Maximum Phase:
2
First Approval:
None
UNII:
4RTO57VG65
Molecule Type:
Small molecule
Molecular Formula:
C12H18O4
Molecular Weight:
226.27
AlogP:
1.64
PSA:
52.6
HBD:
0.0
HBA:
#RotB:
8.0
Source:
POLYSTYRENE SULFONATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
POLYSTYRENE SULFONATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORG-34517
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Depressive Disorder; Depressive Disorder, Major
Glucocorticoid receptor antagonist
ORG-34517
×
Maximum Phase:
2
First Approval:
None
UNII:
17VAN37K4Y
Molecule Type:
Small molecule
Molecular Formula:
C28H30O4
Molecular Weight:
430.54
AlogP:
5.07
PSA:
55.76
HBD:
1.0
HBA:
#RotB:
1.0
Source:
EPETIRIMOD
2
Small molecule
Investigational
Unknown
Unknown
Papillomavirus Infections
Unknown
EPETIRIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
9P5MH9F521
Molecule Type:
Small molecule
Molecular Formula:
C13H15N5
Molecular Weight:
241.3
AlogP:
2.22
PSA:
69.62
HBD:
1.0
HBA:
#RotB:
2.0
Source:
INDANTADOL
2
Small molecule
Investigational
Unknown
Unknown
Cough; Diabetic Neuropathies; Neuralgia; Pain
Glutamate [NMDA] receptor antagonist
INDANTADOL
×
Maximum Phase:
2
First Approval:
None
UNII:
Z3867B9SQP
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IODOCARB
2
Small molecule
Investigational
Unknown
Unknown
Fatigue Syndrome, Chronic; Pulmonary Disease, Chronic Obstructive
Unknown
IODOCARB
×
Maximum Phase:
2
First Approval:
None
UNII:
603P14DHEB
Molecule Type:
Small molecule
Molecular Formula:
C8H12INO2
Molecular Weight:
281.09
AlogP:
1.91
PSA:
38.33
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ENMD-2076
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Multiple Myeloma; Neoplasms; Adenocarcinoma, Clear Cell; Breast Neoplasms; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma
Fibroblast growth factor receptor 3 inhibitor
ENMD-2076
×
Maximum Phase:
2
First Approval:
None
UNII:
J6U9WP10T7
Molecule Type:
Small molecule
Molecular Formula:
C21H25N7
Molecular Weight:
375.48
AlogP:
3.17
PSA:
72.97
HBD:
2.0
HBA:
#RotB:
5.0
Source:
AR-67
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Gliosarcoma; Myelodysplastic Syndromes
Unknown
AR-67
×
Maximum Phase:
2
First Approval:
None
UNII:
3YEA04NV6H
Molecule Type:
Small molecule
Molecular Formula:
C26H30N2O5Si
Molecular Weight:
478.62
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
VELUSETRAG
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Gastroparesis
Serotonin 4 (5-HT4) receptor agonist
VELUSETRAG
×
Maximum Phase:
2
First Approval:
None
UNII:
J4VNV64ARB
Molecule Type:
Small molecule
Molecular Formula:
C25H36N4O5S
Molecular Weight:
504.65
AlogP:
1.56
PSA:
111.95
HBD:
2.0
HBA:
#RotB:
8.0
Source:
DE-112
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DE-112
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DARIGABAT
2
Small molecule
Investigational
Unknown
Unknown
Panic Disorder; Anxiety Disorders; Epilepsy, Reflex; Low Back Pain; Seizures
GABA-A receptor; anion channel agonist
DARIGABAT
×
Maximum Phase:
2
First Approval:
None
UNII:
O9BP19HZ3Q
Molecule Type:
Small molecule
Molecular Formula:
C22H21FN4O3S
Molecular Weight:
440.5
AlogP:
4.12
PSA:
86.97
HBD:
0.0
HBA:
#RotB:
6.0
Source:
FLUZOPARIB
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Nasopharyngeal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
FLUZOPARIB
×
Maximum Phase:
2
First Approval:
None
UNII:
TWF0ML1CK8
Molecule Type:
Small molecule
Molecular Formula:
C22H16F4N6O2
Molecular Weight:
472.4
AlogP:
2.92
PSA:
96.77
HBD:
1.0
HBA:
#RotB:
3.0
Source:
1
2
…
134
135
136
137
138
139
140
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA